Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results new illness compatible with Covid-19 Esymptomatic Covid-19 Econversion to SARS-CoV- 2–positive status via NP swab E

COVID 19 outpatients meta-analysis

COPE – Coalition V
  NCT04466540		 RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
689/683 inconclusive
PATCH Cohort 1 (Amaravadi)
  NCT04329923		 RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
15/13 inconclusive
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis)
  NCT04304053		 RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
137/157 safety concern
COVID-PEP Severity (Skipper)
  NCT04308668		 RCThydroxychloroquinecontrolCOVID 19 outpatientssome concern
244/247 no results
COVID-PEP Severity (Skipper)
  NCT04308668		 RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
244/247 safety concern
3 studies excluded by filtering options (2 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons